Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Global program seeks to confirm biosimilarity to support regulatory submissions in the US and EU.

Sandoz Launches Phase III Clinical Trial for Biosimilar Etanercept

A conversation with Kevin Brady of Alkermes about how high potency APIs are changing the way drugs are developed and manufactured in terms of process, equipment and regulations, including a case study that demonstrates the effective scale up or manufacture of a drug with a highly potent API.

High Potency APIs Video

A screening method predicts delamination in primary packaging.

Evaluating Parenteral Packaging for Glass Delamination

Semi-automatic technology aids egg-based influenza vaccine production in smaller facility footprints.

RAME-HART Technology Helps Boost Vaccine Production in Emerging Markets

PSL has developed a microsphere refiner for microsphere formulation, from small scale processes to commercial production.

PSL Develops Microsphere Refiner for Formulation of Microspheres

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Aseptic connectors provide the flexibility and robustness needed for modern parenteral manufacturing operations.

Will Aseptic Connectors Make Production Outside of the Cleanroom Possible?

The lipid-based method provides a tool for delivery of highly potent, poorly soluble, and unstable APIs. And new in-process capsule printing and shell technologies expand softgelsâ€™ applications further.

Advancing Softgel Technology for Poorly Soluble or Highly Potent APIs

Conjugated vaccines are meeting the need for longer-lasting immune responses, but the production process is complex, and manufacturers are looking for simpler solutions.

Single-Use Systems and Chromatography Purification Techniques Improve Conjugate Vaccine Manufacturing

EMA's revised guideline on biosimilars containing biotechnology-derived proteins is published for public consultation.

EMA Revises Biosimilars Guideline

Facility will use mammalian cell-culture technology and be ready for operations by 2016.